Tibsovo plus Vidaza led to survival benefit for patients with IDH1-mutant acute myeloid leukemia, according to findings from the AGILE clinical trial. Findings from the phase 3 AGILE trial showed ...

Vidaza has been designated as an Orphan Medicinal Product in the EU for the treatment of MDS, which, if approved, entitles the drug to ten years of market exclusivity for the approved indication.

Previously, Vidaza alone showed poor response rates for patients with TP53-mutated, myelodysplastic syndromes and acute myeloid leukemia, but adding the novel agent eprenetapopt improved response ...

Two year survival rate of 50.8 percent for Vidaza versus 26.2 for conventional care regimens 9.4 months median survival benefit for patients on Vidaza compared to conventional care regimens Only agent ...

Celgene announced results from a Phase 2 study evaluating the combination of Revlimid (lenalidomide) plus Vidaza (azacitidine) in patients ≥60 years with untreated acute myeloid leukemia (AML).

VIDAZA was compared with low–dose Ara–C in the UK and France, and compared with best supportive care in Germany, Italy, Sweden, Greece, Spain and the Netherlands. In both groups, VIDAZA consistently ...

" VIDAZA offers patients significantly improved overall survival with less myelosuppression than occurs with low dose Ara–C, and should be considered for first–line therapy, " said Professor Pierre ...

If a recent survey of 100 hematologists and oncologists is any indicator, then Vidaza (azacitidine), Pharmion Corp.'s pyrimidine nucleoside analogue approved in May, could be poised to snag a major ...

BOSTON, Dec. 9 (Reuters) - Pharmion Corp said on Sunday that detailed analysis of a late-stage clinical trial of its drug to treat a group of blood disorders known as myelodysplastic syndromes ...

Patients in the UK with myelodysplastic syndromes will be celebrating news that the National Institute for Health and Clinical Excellence has been ordered to reassess Celgene’s Vidaza for the National ...

On May 19, 2004, Vidaza became the first drug approved by the FDA for the treatment of patients with Myelodysplastic Syndromes (MDS). The FDA approved Vidaza, the first in a new class of drugs called ...